AZTA
Price
$37.14
Change
+$1.59 (+4.47%)
Updated
Nov 3 closing price
Capitalization
1.63B
6 days until earnings call
Intraday BUY SELL Signals
ICLR
Price
$203.77
Change
-$1.37 (-0.67%)
Updated
Nov 3 closing price
Capitalization
15.72B
112 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

AZTA vs ICLR

AZTA vs ICLR Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
AZTA vs. ICLR commentary
Nov 04, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AZTA is a StrongBuy and ICLR is a Buy.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for AZTA with price predictions
Nov 03, 2026

AZTA in upward trend: price rose above 50-day moving average on October 19, 2026

AZTA moved above its 50-day moving average on October 19, 2026 date and that indicates a change from a downward trend to an upward trend. In 33 of 39 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 85%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 27, 2026. You may want to consider a long position or call options on AZTA as a result. In 66 of 85 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 78%.

Following a +5.60% 3-day Advance, the price is estimated to grow further. Considering data from situations where AZTA advanced for three days, in 213 of 297 cases, the price rose further within the following month. The odds of a continued upward trend are 72%.

The Aroon Indicator entered an Uptrend today. In 131 of 177 cases where AZTA Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 74%.

Bearish Trend Analysis

The 10-day RSI Indicator for AZTA moved out of overbought territory on October 30, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 30 similar instances where the indicator moved out of overbought territory. In 22 of the 30 cases, the stock moved lower in the following days. This puts the odds of a move lower at 73%.

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 45 of 60 cases where AZTA's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 75%.

The Moving Average Convergence Divergence Histogram (MACD) for AZTA turned negative on November 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In 35 of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at 71%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where AZTA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.

AZTA broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Seasonality Score of 3 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of 12 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.077) is normal, around the industry mean (4.946). P/E Ratio (-13.807) is within average values for comparable stocks, (38.797). Projected Growth (PEG Ratio) (0.310) is also within normal values, averaging (4.143). Dividend Yield (0.011) settles around the average of (0.005) among similar stocks. P/S Ratio (2.485) is also within normal values, averaging (56.876).

The Tickeron Price Growth Rating for this company is 38 (best 1 - 100 worst), indicating steady price growth. AZTA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 93 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AZTA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

A.I.Advisor
a Summary for ICLR with price predictions
Nov 03, 2026

ICLR's MACD Histogram crosses above signal line

The Moving Average Convergence Divergence (MACD) for ICLR turned positive on October 15, 2026. Looking at past instances where ICLR's MACD turned positive, the stock continued to rise in 32 of 43 cases over the following month. The odds of a continued upward trend are 74%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on ICLR as a result. In 64 of 95 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 67%.

ICLR moved above its 50-day moving average on October 14, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for ICLR crossed bullishly above the 50-day moving average on October 20, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 10 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 67%.

Following a +17.76% 3-day Advance, the price is estimated to grow further. Considering data from situations where ICLR advanced for three days, in 202 of 305 cases, the price rose further within the following month. The odds of a continued upward trend are 66%.

The Aroon Indicator entered an Uptrend today. In 137 of 220 cases where ICLR Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 62%.

Bearish Trend Analysis

The 10-day RSI Indicator for ICLR moved out of overbought territory on November 02, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 29 similar instances where the indicator moved out of overbought territory. In 21 of the 29 cases, the stock moved lower in the following days. This puts the odds of a move lower at 72%.

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 9 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ICLR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 69%.

ICLR broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 1 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. ICLR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 90 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of 93 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.676) is normal, around the industry mean (65.986). ICLR's P/E Ratio (304.134) is considerably higher than the industry average of (3.066). Projected Growth (PEG Ratio) (0.533) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (1.626) is also within normal values, averaging (9.775).

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ICLR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 85, placing this stock worse than average.

FUNDAMENTALS RATINGS
AZTA vs ICLR: Fundamental Ratings
AZTA
ICLR
OUTLOOK RATING
1..100
2790
VALUATION
overvalued / fair valued / undervalued
1..100
12
Undervalued
93
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9390
PRICE GROWTH RATING
1..100
3835
P/E GROWTH RATING
1..100
981
SEASONALITY SCORE
1..100
3n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

AZTA's Valuation (12) in the Electronic Production Equipment industry is significantly better than the same rating for ICLR (93) in the Pharmaceuticals Other industry. This means that AZTA’s stock grew significantly faster than ICLR’s over the last 12 months.

AZTA's Profit vs Risk Rating (100) in the Electronic Production Equipment industry is in the same range as ICLR (100) in the Pharmaceuticals Other industry. This means that AZTA’s stock grew similarly to ICLR’s over the last 12 months.

ICLR's SMR Rating (90) in the Pharmaceuticals Other industry is in the same range as AZTA (93) in the Electronic Production Equipment industry. This means that ICLR’s stock grew similarly to AZTA’s over the last 12 months.

ICLR's Price Growth Rating (35) in the Pharmaceuticals Other industry is in the same range as AZTA (38) in the Electronic Production Equipment industry. This means that ICLR’s stock grew similarly to AZTA’s over the last 12 months.

ICLR's P/E Growth Rating (1) in the Pharmaceuticals Other industry is significantly better than the same rating for AZTA (98) in the Electronic Production Equipment industry. This means that ICLR’s stock grew significantly faster than AZTA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AZTAICLR
RSI
ODDS (%)
Bearish Trend 1 day ago
73%
Bearish Trend 1 day ago
72%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
75%
Bearish Trend 1 day ago
75%
Momentum
ODDS (%)
Bullish Trend 1 day ago
78%
Bullish Trend 1 day ago
67%
MACD
ODDS (%)
Bearish Trend 1 day ago
71%
Bullish Trend 1 day ago
74%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
80%
Bullish Trend 1 day ago
69%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
81%
Bullish Trend 1 day ago
69%
Advances
ODDS (%)
Bullish Trend 7 days ago
72%
Bullish Trend 7 days ago
66%
Declines
ODDS (%)
Bearish Trend 3 days ago
81%
Bearish Trend 1 day ago
69%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
78%
Bearish Trend 1 day ago
71%
Aroon
ODDS (%)
Bullish Trend 1 day ago
74%
Bullish Trend 1 day ago
62%
COMPARISON
Comparison
Nov 04, 2026
Stock price -- (AZTA: $37.14 vs. ICLR: $203.77)
Brand notoriety: AZTA and ICLR are both not notable
AZTA represents the Pharmaceuticals: Other, while ICLR is part of the Medical Specialties industry
Current volume relative to the 65-day Moving Average: AZTA: 99% vs. ICLR: 126%
Market capitalization -- AZTA: $1.63B vs. ICLR: $15.72B
AZTA [@Pharmaceuticals: Other] is valued at $1.63B. ICLR’s [@Medical Specialties] market capitalization is $15.72B. The market cap for tickers in the [@Pharmaceuticals: Other] industry ranges from $126 to $155.71B. The market cap for tickers in the [@Medical Specialties] industry ranges from $27 to $4.39T. The average market capitalization across the [@Pharmaceuticals: Other] industry is $9.49B. The average market capitalization across the [@Medical Specialties] industry is $21.14B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AZTA’s FA Score shows that 1 FA rating(s) are green while ICLR’s FA Score has 1 green FA rating(s).

  • AZTA’s FA Score: 1 green, 4 red.
  • ICLR’s FA Score: 1 green, 4 red.
According to our system of comparison, both AZTA and ICLR are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AZTA’s TA Score shows that 4 TA indicator(s) are bullish while ICLR’s TA Score has 6 bullish TA indicator(s).

  • AZTA’s TA Score: 4 bullish, 5 bearish.
  • ICLR’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, ICLR is a better buy in the short-term than AZTA.

Price Growth

AZTA (@Pharmaceuticals: Other) experienced а -4.96% price change this week, while ICLR (@Medical Specialties) price change was +11.36% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was -0.70%. For the same industry, the average monthly price growth was -1.70%, and the average quarterly price growth was +10.08%.

The average weekly price growth across all stocks in the @Medical Specialties industry was -2.30%. For the same industry, the average monthly price growth was -5.24%, and the average quarterly price growth was +42.12%.

Reported Earning Dates

AZTA is expected to report earnings on Nov 10, 2026.

ICLR is expected to report earnings on Feb 24, 2027.

Industries' Descriptions

@Pharmaceuticals: Other (-0.70% weekly)

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

@Medical Specialties (-2.30% weekly)

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

View a ticker or compare two or three
Interact to see
Advertisement

AZTA and

Correlation & Price change

A.I.dvisor indicates that over the last year, AZTA has been loosely correlated with IQV. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if AZTA jumps, then IQV could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AZTA
1D Price
Change %
AZTA100%
+4.47%
IQV - AZTA
60%
Loosely correlated
+1.61%
RVTY - AZTA
59%
Loosely correlated
+7.84%
A - AZTA
59%
Loosely correlated
+2.02%
MTD - AZTA
59%
Loosely correlated
+1.18%
BRKR - AZTA
58%
Loosely correlated
+1.45%
More

ICLR and

Correlation & Price change

A.I.dvisor indicates that over the last year, ICLR has been loosely correlated with RGEN. These tickers have moved in lockstep 62% of the time. This A.I.-generated data suggests there is some statistical probability that if ICLR jumps, then RGEN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ICLR
1D Price
Change %
ICLR100%
-0.67%
RGEN - ICLR
62%
Loosely correlated
+3.08%
IQV - ICLR
55%
Loosely correlated
+1.61%
BRKR - ICLR
54%
Loosely correlated
+1.45%
TMO - ICLR
47%
Loosely correlated
+2.30%
AZTA - ICLR
45%
Loosely correlated
+4.47%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
RCKT2.510.04
+1.62%
Rocket Pharmaceuticals
EQNR45.630.23
+0.51%
Equinor ASA
AERT5.71-0.24
-4.03%
Aeries Technology Inc.
NBR81.22-3.46
-4.09%
Nabors Industries Ltd
DUOL128.00-7.27
-5.37%
Duolingo